Home COVID-19 updates BDR Pharma plans to launch 400 mg Favipiravir Tablets to treat COVID-19...

BDR Pharma plans to launch 400 mg Favipiravir Tablets to treat COVID-19 Patients

Indian drug firm, BDR Pharmaceuticals on Friday( 4/9/2020), informed that they are planning to launch 400 mg Favipiravir tablets, that will be used to treat COVID-19 patients in the country.

“Favipiravir tablets or ‘BDFAVI’ 400 mg tablets, in short, will be priced at ₹990 for a strip of 10 tablets and each tablet will cost ₹99”, BDR Pharma said in an official statement.

This isn’t the first venture of BDR pharma. Last August, the same company launched 200 mg Favipiravir tablets, that have been used to treat patients with mild symptoms of coronavirus.

BDR Pharma Founder and CMD, Dharmesh Shah said that they are aiming to make BDFAVI available in sufficient quantities to meet the high demand for the drug in the Indian market, to help curb the current crisis and introducing a higher dosage is an attempt to ensure a smoother experience to patients and caregivers.

The company has also informed in the statement that they had received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate COVID-19 symptoms, under the brand name BDFAVI.

Favipiravir is an antiviral medication used to treat influenza It is also being studied to treat several other viral infections like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazine carboxamide derivative.

Till now, seven Indian Pharma companies are in the race to develop a vaccine against COVID-19, of which three vaccines are ahead in the race. This includes the vaccine, manufactured by Serum Institute, which is now under phase 2B and 3, where 1700 patients would be studied. The second one is the vaccine, developed by Bharat Biotech, which has completed phase 1 study with 375 patients and about to begin phase 2. The last one is from Zydus Cadila, which has completed phase 1 with around 50-75 patients and is about to begin its second phase.

AlSO READ- India in talks with Russia for COVID-19 vaccine

With 3.94 million cases and 68,472 deaths, Indian has been ranked third globally with the maximum number of COVID-19 cases and drugs like ‘BDFAVI’ 400 mg are a ray of hope now.